Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDP.L Regulatory News (IDP)

  • There is currently no data for IDP

Trading Update

12 Jan 2022 07:00

RNS Number : 1362Y
InnovaDerma PLC
12 January 2022
Β 

Β 

InnovaDerma PLC

Β ("InnovaDerma" or the "Company")

Trading Update

InnovaDermaΒ (LSE: IDP), a leading digitally focused UKΒ beauty brand developer, is pleased to provide a trading update for the six months ended 31 December 2021.

H1 Trading Statement

Our strategy of driving increased profitable sales through gross margin improvement, radical simplification of business operations, rigorous cost control and the prioritisation of our Skinny Tan brand, is working.

Β· Financial performance is markedly improved vs H1 2020 as our previously announced strategy is implemented with a disciplined approach to marketing and overhead costs.

Β· Short-term impact on revenue (revenues of c. Β£3.7m versus H1 20: Β£4.1m) primarily driven by ceasing loss-making sales promotions and reducing marketing investment in lower priority brands such as Nuthing.

Β· Gross margin improvements and operational cost reductions remain robust despite global raw material pricing pressures. We are also benefitting from stronger control over warehousing and logistics costs.

Β· Over the period, we have further improved our return on marketing spend and have adopted a strategy of reducing less efficient marketing spend during the low tanning season to ensure we have the right ammunition to maximise returns over the peak H2 tanning season (UK + US).

Β· Our Liberty Poole collaboration continues to yield benefits and is helping to increase the share of our business in the key 18-25 age group. We expect this collaboration to be further enhanced when Liberty appears as a contestant on ITV's hit TV series, Dancing On Ice, which starts on the 16th January.

Skinny Tan is the Company's largest (84% of revenue) and highest priority future growth driver. The previously communicated strategic decision to move away from certain loss leading sales led to a reduction in sales but is consistent with the Group's strategic focus on longer-term profitability. Amazon is now the Company's 3rd largest retailer, with further significant future growth anticipated as we enter the peak tanning season. This sales channel is becoming increasingly significant whilst allowing us to achieve a healthy margin.

Charles + Lee has shown excellent retail sales growth though revenues of c. Β£0.3m remain slightly below last year (H1 20: Β£0.4m). Positioned around 'No-nonsense, high-performance Aussie-made male grooming' we are successfully focusing the brand at the entry premium tier, adjusting pricing up c.10%, and with excellent growth potential.

Investment in Roots and Nuthing has been deprioritised as we focus on Skinny Tan and Charles + Lee as the Company's priority growth brands.

As previously announced, the Company entered into a Joint Venture for the Prolong brand in Dec 2021. We believe this will maximise shareholder value in the mid-term and we are very optimistic for its future. Prolong revenues prior to the partnership agreement are included in our consolidated figures. Revenues after the partnership agreement are excluded from our consolidated figures and from future forecasts, however, InnovaDerma will directly benefit from any future dividends which are paid by the Joint Venture and/or any proceeds achieved by a future sale of the business.

Over the past month, the Joint Venture has made good progress and has recently launched an interim US website re-design which better represents the brand and improves the consumer experience. During this quarter, the Joint Venture will execute upon its digital marketing strategy across Facebook, Instagram and TikTok whilst also utilising Googles Ad network to drive website traffic and revenue growth.

Outlook

The Board remains optimistic that the transformation plan enacted this year, as well as underlying improved consumer consumption and retail momentum versus last year will enable the business to continue its improvement trajectory with a return to profitability this year remaining the Board's intention. The recent and fast rise of Omicron, with the associated reduction in social contacts, has had a cooling effect on pre-Christmas trade in the UK. We continue to monitor this closely but have already begun to see the start of a "bounce back" which we believe will continue into the peak tanning season in the UK, the second half of our financial year has historically been stronger than the first and this is expected to be the case again this year.

Blake Hughes, CEO InnovaDerma PLC, commented:

Β 

"We are making strong progress in simplifying and reshaping our business as we focus on delivering sustainable, profitable revenue growth. We are delivering against our profit improvement plans as set out in this update and I am pleased to see the focus on Amazon and our exciting Liberty Poole collaboration are already delivering strong benefits, even before peak tanning season. In addition, Charles + Lee has had another record-breaking season at Myer despite Australian lock downs. Whilst Omicron has presented some short-term uncertainty, I believe that we will see a significantly stronger tanning season in the six months ahead. We have a strong foundation for the second half of the year which will be further supported by exciting new product launches on Skinny Tan which have already received excellent retailer support. The Board and I are confident of the future and our focus on returning the Company to profitability, as described in this update."

Β 

Further enquiries

InnovaDerma

Blake Hughes

Β 

c/o TB Cardew

finncap Ltd

Geoff Nash/Kate Bannatyne

Alice LaneΒ - Corporate Broking

Β 

+44 (0)207 220 0500

www.finncap.com

TB Cardew

Β 

Shan Shan Willenbrock/

+ 44 (0)7775 848537

OliviaΒ Rosser

+Β 44Β (0)7552 864250

Β 

innovaDerma@tbcardew.com

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTEAEFFFSPAEAA
Date   Source Headline
31st May 20221:57 pmRNSScheme of Arrangement Becomes Effective
27th May 20224:01 pmRNSCourt Sanction of Scheme and Suspension
27th May 202210:21 amRNSForm 8.5 (EPT/RI)
25th May 202211:10 amRNSForm 8.5 (EPT/RI)
24th May 202211:48 amRNSForm 8.5 (EPT/RI)
23rd May 202211:49 amRNSForm 8.5 (EPT/RI)
19th May 20223:29 pmRNSResults of Court Meeting and General Meeting
19th May 20229:47 amRNSForm 8.5 (EPT/RI)
16th May 202210:35 amRNSForm 8.5 (EPT/RI)
12th May 202210:13 amRNSForm 8.5 (EPT/RI)
10th May 20229:05 amRNSForm 8.5 (EPT/RI)
9th May 202211:45 amRNSForm 8.5 (EPT/RI)
5th May 202210:00 amRNSScheme Timetable
5th May 20229:04 amRNSForm 8.5 (EPT/RI)
4th May 20229:51 amRNSForm 8.5 (EPT/RI)
3rd May 202210:48 amRNSForm 8.3 - InnovaDerma plc
3rd May 202210:29 amRNSForm 8.5 (EPT/RI)
27th Apr 202211:06 amRNSForm 8.5 (EPT/RI)
25th Apr 20221:31 pmRNSForm 8.3 - InnovaDerma PLC
25th Apr 202212:35 pmRNSPublication of Circular/Notice of General Meeting
25th Apr 202212:30 pmRNSPosting of Scheme Document & IMC Presentation
21st Apr 20221:00 pmRNSForm 8.3 - InnovaDerma PLC
20th Apr 202212:07 pmRNSForm 8.5 (EPT/RI) - InnovaDerma PLC
14th Apr 20229:34 amRNSForm 8.5 (EPT/RI) - InnovaDerma PLC
13th Apr 20226:06 pmRNSForm 8.3 - Innovaderma PLC
13th Apr 20224:30 pmRNSForm 8 (OPD) - InnovaDerma plc
13th Apr 20224:03 pmRNSForm 8.3 - Offeree - InnovaDerma PLC
13th Apr 202211:40 amRNSForm 8.3 - InnovaDerma PLC
13th Apr 20228:47 amRNSForm 8.5 (EPT/RI) - InnovaDerma PLC
13th Apr 20227:00 amRNSForm 8.3 - InnovaDerma PLC
12th Apr 202212:31 pmRNSForm 8.3 - InnovaDerma plc
11th Apr 20226:14 pmRNSForm 8 (OPD) InnovaDerma PLC
8th Apr 20223:00 pmRNSForm 8 (OPD) - InnovaDerma plc
8th Apr 202210:33 amRNSForm 8.5 (EPT/RI)
7th Apr 20229:51 amRNSForm 8.5 (EPT/RI)
6th Apr 202211:03 amRNSForm 8.5 (EPT/RI)
5th Apr 20221:01 pmRNSForm 8.3 - Innovaderma PLC
5th Apr 202211:25 amRNSForm 8.3 - InnovaDerma PLC
4th Apr 202211:16 amRNSForm 8.5 (EPT/RI)
1st Apr 20225:32 pmRNSForm 8.3 - Innovaderma PLC
1st Apr 202211:56 amRNSForm 8.5 (EPT/RI)
1st Apr 202211:00 amRNSForm 8 (DD) - InnovaDerma PLC
31st Mar 20224:44 pmRNSForm 8.3 - Innovaderma Plc
31st Mar 20224:41 pmRNSSecond Price Monitoring Extn
31st Mar 20224:36 pmRNSPrice Monitoring Extension
31st Mar 20222:05 pmRNSSecond Price Monitoring Extn
31st Mar 20222:00 pmRNSPrice Monitoring Extension
31st Mar 20227:01 amRNSRecommended Merger with InnovaDerma Plc
31st Mar 20227:00 amRNSInterim Results
27th Jan 20224:10 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.